Add office photos
Employer?
Claim Account for FREE
Lupin
4.1
based on 6.5k Reviews
Video summary
Proud winner of ABECA 2025 - AmbitionBox Employee Choice Awards
Company Overview
Associated Companies
Company Locations
Working at Lupin
Company Summary
Global pharmaceutical leader, reporting over ₹20,000 crore in FY24 revenue and a leading global manufacturer of generic medicines with a product footprint in more than 100 countries.
Overall Rating
4.1/5
based on 6.5k reviews
5% above
industry average
Highly rated for
Company culture, Skill development, Work-life balance
Work Policy
Work from office
83% employees reported
Monday to Saturday
59% employees reported
Flexible timing
53% employees reported
No travel
47% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
532 employees reported
Health insurance
476 employees reported
Office cab/shuttle
327 employees reported
Cafeteria
211 employees reported
View all benefits
About Lupin
Founded in1968 (57 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersMumbai, Maharashtra, India
Office Locations
Websitelupin.com
Primary Industry
Other Industries
Are you managing Lupin's employer brand? To edit company information,
claim this page for free
View in video summary
Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. Lupin is a significant player in the therapy areas of Gynaecology, Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lupin also holds a global leadership position in the Anti-TB and Cephalosporins segments. With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.
Report error
Managing your company's employer brand?
Claim this Company Page for FREE
ABECA - AmbitionBox Employee Choice Awards
Best of the best, rated by employees
Lupin won India’s Largest Employee Choice Awards in Large Companies Category.
Top Rated Large Company
Top Rated Pharma Company
Share
Lupin Ratings
based on 6.5k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.3k
4
1.9k
3
727
2
234
1
386
Category Ratings
4.0
Company culture
4.0
Skill development
3.9
Work-life balance
3.8
Salary
3.8
Work satisfaction
3.7
Job security
3.5
Promotions
Lupin is rated 4.1 out of 5 stars on AmbitionBox, based on 6.5k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Lupin
based on 6.2k reviews
4.0
Rated by 398 Women
Rated 3.9 for Work-life balance and 3.9 for Company culture
4.1
Rated by 5.8k Men
Rated 4.1 for Skill development and 4.0 for Company culture
Work Policy at Lupin
based on 702 reviews in last 6 months
Work from office
83%
Hybrid
11%
Permanent work from home
6%
Lupin Reviews
Top mentions in Lupin Reviews
+ 5 more
Compare Lupin with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 6.5k reviews | 4.1/5 based on 6.4k reviews | 4.0/5 based on 7.3k reviews | 4.1/5 based on 7.4k reviews |
Highly Rated for | Skill development Company culture Work-life balance | Salary Skill development Work-life balance | Skill development Company culture Work-life balance | Skill development Salary Work-life balance |
Critically Rated for | No critically rated category | No critically rated category | Promotions | No critically rated category |
Primary Work Policy | Work from office 83% employees reported | Work from office 84% employees reported | Work from office 73% employees reported | Work from office 73% employees reported |
Rating by Women Employees | 4.0 Good rated by 398 women | 4.0 Good rated by 407 women | 3.9 Good rated by 830 women | 4.0 Good rated by 748 women |
Rating by Men Employees | 4.1 Good rated by 5.8k men | 4.0 Good rated by 5.4k men | 4.0 Good rated by 6.1k men | 4.1 Good rated by 6.3k men |
Job security | 3.7 Good | 3.8 Good | 3.5 Good | 3.7 Good |
View more
Lupin Salaries
Lupin salaries have received with an average score of 3.8 out of 5 by 6.5k employees.
Officer
(1.8k salaries)
Unlock
₹1.5 L/yr - ₹9 L/yr
Research Associate
(827 salaries)
Unlock
₹2 L/yr - ₹8.6 L/yr
Production Officer
(578 salaries)
Unlock
₹2.1 L/yr - ₹6.8 L/yr
Junior Officer
(467 salaries)
Unlock
₹2.3 L/yr - ₹8 L/yr
Senior Officer
(455 salaries)
Unlock
₹2.6 L/yr - ₹7.4 L/yr
Area Sales Manager
(344 salaries)
Unlock
₹4.2 L/yr - ₹11 L/yr
Marketing Executive
(324 salaries)
Unlock
₹2.2 L/yr - ₹8 L/yr
Executive Production
(294 salaries)
Unlock
₹3.8 L/yr - ₹12 L/yr
QC Officer
(262 salaries)
Unlock
₹2.6 L/yr - ₹6.4 L/yr
Associate Scientist
(257 salaries)
Unlock
₹5 L/yr - ₹13 L/yr
Lupin Interview Questions
A Quality Control Officer was asked 3mo agoQ. What is the process of gram staining?
A Production Officer was asked Q. Tell me about SALF.
An Executive Production was asked Q. What are change controls?
A Research Associate was asked 10mo agoQ. Can you prepare a presentation?
A System Administrator was asked Q. What is a TCP wrapper?
Lupin Jobs
Popular Designations Lupin Hires for
Lupin News
View all
Lupin inks agreement with Sino Universal for respiratory product in China
- Indian pharmaceutical company Lupin has signed an agreement with Sino Universal for selling Tiotropium DPI in China.
- Lupin will be the marketing authorization holder and responsible for manufacturing the product, while SUP will secure regulatory approvals for the sale.
- The partnership will help Lupin expand its presence in China.
- Tiotropium DPI is effective in enhancing lung function and improving the quality of life for individuals with respiratory conditions.
- Fabrice Egros, Lupin's President of Corporate Development, highlighted the commitment to developing essential products for respiratory disease treatment.
- Wang Li, President of SUP, emphasized that the collaboration aims to enhance respiratory care and introduce superior products to the Chinese market.
- The goal is to provide more patients in China access to high-quality and innovative respiratory health solutions.
- The agreement was announced on June 16, 2025.
HinduBusinessLine | 16 Jun, 2025
A ‘test case’ unfolds over Novo Nordisk’s weight loss and diabetes drug semaglutide
- Novo Nordisk is in a patent infringement battle with Dr Reddy's Laboratories and OneSource Specialty Pharma over the weight loss and diabetes drug semaglutide.
- Last week, Dr Reddy's Laboratories stated in Delhi High Court that they won't sell the product in India without a local license, though they have a license to manufacture and export to countries without a Novo patent.
- This legal case is considered a 'test case' for drugmakers aiming to enter the semaglutide market, with implications for companies like Cipla, Lupin, and Glenmark who intend to produce the drug in India.
- Semaglutide patents will expire in Canada next January and in India a few months later, raising questions about export destinations and legal implications for infringement under different countries' laws.
HinduBusinessLine | 2 Jun, 2025
Novo Nordisk diabetes / weightloss drug semaglutide locked in a legal tangle with DRL
- Novo Nordisk's drug semaglutide, also known as Ozempic / Wegovy, faces a legal dispute with Dr Reddy’s Laboratories (DRL) in India over patent infringement.
- DRL informed the Delhi High Court that they do not have a license to sell the drug in India and will not do so until they obtain one.
- Indian drugmakers like Cipla, Lupin, and Glenmark are eyeing the opportunity presented when some semaglutide patents expire next year.
- Novo Nordisk and DRL are engaged in a legal battle over the export of the drug to countries where Novo Nordisk does not hold a patent, with the case scheduled for August 19.
HinduBusinessLine | 31 May, 2025
Stock Market Today: All You Need To Know Before Going Into Trade On May 26
- On Friday, NSE Nifty 50 closed 243.45 points higher, while BSE Sensex ended 769 points up.
- Foreign portfolio investors turned net buyers on Friday, purchasing Indian equities worth Rs 1,794.59 crore.
- Domestic institutional investors remained net buyers for the fourth consecutive day, buying equities worth Rs 299.78 crore.
- Key stocks to watch for earnings include Aurobindo Pharma, Blue Dart Express, and Maharashtra Seamless, among others.
- JSW Steel reported Q4 highlights with increased revenue, Ebitda, net profit, and capacity utilization achievements.
- Several companies announced earnings, including Balkrishna Industries, Glenmark Pharma, Reliance Infrastructure, and more.
- Stocks in the news: Bharti Airtel, TVS Srichakra, Lupin, Sun Pharma, and others shared updates on orders, investments, and developments.
- Bulk deals involved companies like Cartrade Tech, Gravita India, and Interarch Building Solutions, among others.
- IPO offerings from companies such as Belrise Industries, Aegis Vopak Terminals, and Schloss Bangalore were subscribed or set for bidding.
- Trading tweaks included price band changes, ex-dividend declarations, block deals, F&O cues, and a currency update on the Indian rupee.
Bloomberg Quint | 26 May, 2025
Heard On The Street: Dealers Spot Action In PB Fintech, Delhivery, Anant Raj, Lupin, UPL, Among Others
- Dealers spotted potential block deals in PB Fintech and Delhivery, while Anant Raj may announce fundraise through qualified institutional placement route.
- Astra Microwave's board to meet on May 20 for a fundraise consideration, Lupin and UPL witnessed a lot of buying interest from large HNIs.
- HUDCO, Laurus Labs, and SRF observed buy flows on mutual fund desk, and FII desks engaged in basket buying of two-wheeler OEM names like Bajaj Auto, Eicher Motors, and Hero Moto.
- The information provided in NDTV Profit's 'Heard On The Street' is based on dealing room channel checks and should not be considered as financial advice.
Bloomberg Quint | 19 May, 2025
Lupin clocks 113% growth in Q4 net profit at ₹782 crore
- Lupin recorded a 113% growth in Q4 net profit at ₹782 crore, with sales for the period reaching ₹5,562 crore, a 13.6% increase from the previous year.
- For the financial year ending March 31, 2025, Lupin's profit after tax (PAT) was ₹3,306 crore, up almost 71% from the previous fiscal year, with sales reaching ₹22,192 crore, a 13% increase from the previous year.
- Lupin's North America branch saw revenues of ₹8,395 crore in FY25, accounting for 38% of global sales, while the India formulation sales reached ₹7,577 crore, accounting for 34% of Lupin's global sales.
- The company highlighted achievements such as receiving seven USFDA approvals, launching two new products, and maintaining a strong position in the US generic market with 138 generic products.
HinduBusinessLine | 15 May, 2025
Stock Market Live: GIFT Nifty Hints Muted Start; Eicher Motors, Brigade Enterprises, Wipro Shares In Focus
- Asian indices trading lower may impact the Nifty 50 and Sensex today.
- GIFT Nifty started 0.04% down, indicating a muted start for the benchmarks.
- Companies like Eicher Motors, Brigade Enterprises, Wipro, Tata Power, and Lupin released Q4 results.
- Sensex and Nifty 50 ended with gains yesterday, with Nifty 50 up by 0.36% and Sensex up by 0.22%.
Bloomberg Quint | 15 May, 2025
Stocks To Watch Today: Tata Motors, Bharti Airtel, Raymond, Mahindra Lifespaces, Avenue Supermarts
- Stocks to watch today include Tata Motors, Bharti Airtel, Raymond, Mahindra Lifespaces, and Avenue Supermarts.
- Mahindra Lifespaces approved raising up to Rs 1,500 crore through a rights issue, and other notable actions are expected in the market.
- Companies like Raymond, Avenue Supermarts, Punjab National Bank, Aurobindo Pharma, and others are set for active trading today.
- Earnings reactions to watch include highlights from Siemens, Tata Motors, GlaxoSmithKline Pharmaceuticals, Bharti Hexacom, Bharti Airtel, and more.
- Tata Motors' Q4 consolidated earnings showed marginal revenue growth, Ebitda increase, but a significant net profit decline attributed to one-time tax benefits.
- Bharti Airtel's Q4 results revealed revenue growth, Ebitda increase, margin decline, and a notable net profit decrease partly due to lower tax expenses.
- Other companies like Dalmia Bharat Sugar and Industries also reported positive YoY revenue, Ebitda, and net profit growth in their Q4 results.
- Numerous companies are scheduled to release earnings reports, including Aditya Birla Real Estate, Apollo Tyres, Lupin, Shree Cement, Torrent Power, and more.
- The market is poised to witness significant movements in stock prices and trading activities based on the earnings announcements and market conditions.
- Stay updated with live TV, stock market updates, and business news on NDTV Profit to track the latest developments and make informed investment decisions.
Bloomberg Quint | 14 May, 2025
Tata Power, LIC Housing, Apollo Tyres, Lupin, JSW Energy Q4 Results Today — Earnings Estimates
- Tata Power, LIC Housing, Apollo Tyres, Lupin, JSW Energy are set to post their Q4 results today.
- Tata Power is expected to report revenue of Rs 17,094 crore, Ebitda of Rs 3,094 crore, and a net profit of Rs 1,026 crore.
- Lupin is expected to report revenue of Rs 5,564 crore, Ebitda of Rs 1,244 crore, and a net profit of Rs 735 crore.
- Apollo Tyres is expected to report revenue of Rs 6,633 crore, Ebitda of Rs 899 crore, and a net profit of Rs 306 crore.
Bloomberg Quint | 14 May, 2025
Trump’s move to bring down US medicine prices could take some sheen off India’s drugs, say observers
- The US President is expected to announce a new policy to bring down drug prices in the US and implement a 'most favoured nation' policy.
- This move may impact Indian drugmakers who export generic drugs to the US market as it could lower prices of innovator drugs, affecting the competitiveness of generics.
- Large Indian pharmaceutical companies like Sun Pharma, Dr Reddy’s, Glenmark, Lupin, and Zydus could be affected by this policy change.
- Industry observers are also concerned about the impact on differential pricing strategies of multinational drugmakers in India and possible implications for trade deals with China.
HinduBusinessLine | 12 May, 2025
Powered by
Lupin Subsidiaries
Rubamin
4.1
• 174 reviews
Lupin Digital Health
3.4
• 34 reviews
Polynova Industries
4.1
• 8 reviews
Novel Laboratories Inc
2.0
• 1 review
Report error
Compare Lupin with
Sun Pharmaceutical Industries
4.0
Aurobindo Pharma
4.0
Intas Pharmaceuticals
4.1
Hetero
3.8
Macleods Pharmaceuticals
3.6
Viatris
4.2
Alembic Pharmaceuticals
4.0
Abbott
4.1
Ipca Laboratories
3.9
Glenmark Pharmaceuticals
3.9
Alkem Laboratories
3.9
Mankind Pharma
3.9
Torrent Pharmaceuticals
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.4
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
3.9
DIVI'S Laboratories
3.7
Wockhardt
3.8
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Lupin
Cipla
Manufacturing, Pharma
4.1
• 7.4k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 7.3k reviews
Zydus Lifesciences
Biotech & Life sciences, Pharma
4.1
• 6.4k reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 6.3k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 5.1k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.8k reviews
Hetero
Healthcare / Pharma, Clinical Research, Healthcare, Pharma
3.8
• 3.6k reviews
Macleods Pharmaceuticals
Biotech & Life sciences, Pharma
3.6
• 3.6k reviews
Viatris
Manufacturing, Pharma
4.2
• 3.4k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.3k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.2k reviews
Ipca Laboratories
Pharma
3.9
• 3.1k reviews
Lupin FAQs
When was Lupin founded?
Lupin was founded in 1968. The company has been operating for 57 years primarily in the Pharma sector.
Where is the Lupin headquarters located?
Lupin is headquartered in Mumbai, Maharashtra and has an office in Mumbai.
How many employees does Lupin have in India?
Lupin currently has more than 21,000+ employees in India. Research & Development department appears to have the highest employee count in Lupin based on the number of reviews submitted on AmbitionBox.
Does Lupin have good work-life balance?
Lupin has a Work-Life Balance Rating of 3.9 out of 5 based on 6,400+ employee reviews on AmbitionBox. 79% employees rated Lupin 4 or above, while 21% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Lupin work-life balance reviews for more details.
Is Lupin good for career growth?
Career growth at Lupin is rated fairly well, with a promotions and appraisal rating of 3.5. 79% employees rated Lupin 4 or above, while 21% employees rated it 3 or below on promotions / appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Lupin promotions / appraisals reviews for more detailed insights.
What are the pros and cons of working in Lupin?
Working at Lupin comes with several advantages and disadvantages. It is highly rated for company culture, skill development and work life balance. However, it is poorly rated for promotions / appraisal and job security, based on 6,400+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Trusted by over 1.5 Crore job seekers to find their right fit company
80 Lakh+
Reviews
10L+
Interviews
4 Crore+
Salaries
1.5 Cr+
Users
Contribute to help millions
AmbitionBox Awards
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2025 Info Edge (India) Ltd.
Follow Us
